Literature DB >> 21958312

Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients.

Paolo Vescovi1, Elisabetta Merigo, Marco Meleti, Maddalena Manfredi, Rebecca Guidotti, Samir Nammour.   

Abstract

The osteonecrosis of the jaws (ONJ) is an adverse side effect of long-term bisphosphonate therapy (BPT) firstly described in 2003. The aetiology of BRONJ remains unknown, and the pathogenesis seems multifactorial and related to several local or general factors. Many expert panel developed preventive protocols to facilitate specialists involved in the multidisciplinary management of BRONJ patients. In this paper, we present a concise review of the literature, and we report the experience of the University of Parma with 151 patients that assumed BPT for both oncological (121 patients) and non-oncological (30 patients) diseases. One hundred and thirty-nine BRONJ sites were treated with different approaches (surgical and non-surgical, laser-assisted and non-laser-assisted): in terms of clinical improvement, a statistically significant difference was found between the group treated with the only medical therapy; in terms of complete healing, the introduction in the treatment protocols of both laser-assisted approach and surgical approach improves the therapeutical results.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958312     DOI: 10.1111/j.1600-0714.2011.01091.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  33 in total

Review 1.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

2.  Should jaws positive tracer uptake on scintigraphy be considered a new finding of BRONJ stage 0?

Authors:  G Mergoni; M Meleti; M Manfredi; E Merigo; P Vescovi
Journal:  Ann Stomatol (Roma)       Date:  2013-10-24

3.  Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.

Authors:  Jerome T Higgs; Joo Hyoung Lee; Hong Wang; Vishnu C Ramani; Diptiman Chanda; Cherlene Y Hardy; Ralph D Sanderson; Selvarangan Ponnazhagan
Journal:  Blood Adv       Date:  2017-11-21

Review 4.  Bisphosphonates in multiple myeloma: an updated network meta-analysis.

Authors:  Rahul Mhaskar; Ambuj Kumar; Branko Miladinovic; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2017-12-18

5.  Bone microenvironment-mediated resistance of cancer cells to bisphosphonates and impact on bone osteocytes/stem cells.

Authors:  Abeer Alasmari; Shih-Chun Lin; Serge Dibart; Erdjan Salih
Journal:  Clin Exp Metastasis       Date:  2016-05-07       Impact factor: 5.150

6.  Combined Approach to Treat Medication-Related Osteonecrosis of the Jaws.

Authors:  Elisabetta Merigo; Luigi Cella; Aldo Oppici; Maria Cristina Arbasi; Fabio Clini; Matteo Fontana; Carlo Fornaini
Journal:  J Lasers Med Sci       Date:  2018-03-20

7.  Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up.

Authors:  Cornelio Blus; Serge Szmukler-Moncler; Giulio Giannelli; Gloria Denotti; Germano Orrù
Journal:  Open Dent J       Date:  2013-08-23

Review 8.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

9.  Bisphosphonates and osteonecrosis: an open matter.

Authors:  Paolo Vescovi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

Review 10.  Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy.

Authors:  S Latifyan; M T Genot; J Klastersky
Journal:  Support Care Cancer       Date:  2016-03-31       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.